Changes in disease activity measures and serum chemokine levels of all RA patients (n = 28) before and after 12 weeks of treatment.
| Baseline | Week 12 | p | |
|---|---|---|---|
| CRP, mg/l | 12.2 (5.6–28.3) | 2.1 (1.0–7.7) | < 0.001 |
| ESR, mm/h | 38.0 (25.2–78.7) | 20 (13.5–53.5) | 0.001 |
| Physician global assessment | 6.2 (5.0–8.0) | 3 (1.2–4.2) | 0.001 |
| Swollen joint count | 7.0 (5.0–9.2) | 2 (1.0–6.0) | < 0.001 |
| Tender joint count | 8.0 (4.7–13.2) | 3.0 (1.0–7.0) | 0.002 |
| DAS28 ESR | 5.1 (4.5–5.6) | 3.5 (2.9–4.7) | < 0.001 |
| HAQ score | 1.1 (1.0–1.6) | 1.1 (0.5–1.3) | 0.014 |
| Patient global assessment | 6.0 (6.7–7.0) | 5.0 (3.4–7.0) | 0.04 |
| Serum chemokines, pg/ml | |||
| CXCL10 | 2255.7 (1430.7–4196.1) | 1713.0 (1318.5–2356.5) | < 0.001 |
| CCL2 | 55.8 (30.1–106.0) | 54 (32.2–93.5) | 0.221 |
| CXCL9 | 3062.0 (1245.7–4899.0) | 1302.9 (836.2–2350.3) | < 0.001 |
| CXCL8 | 17.9 (13.1–25.7) | 17.6 (11.0–31.5) | 0.683 |
| CCL5 | 7899.8 (5398.6–9036.9) | 8299.9 (4657.6–11978.6) | 1.0 |
Data are expressed as median (interquartile range). CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; DAS: Disease Activity Score; HAQ: Health Assessment Questionnaire.